{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,11]],"date-time":"2024-06-11T20:42:10Z","timestamp":1718138530784},"reference-count":18,"publisher":"Public Library of Science (PLoS)","issue":"10","license":[{"start":{"date-parts":[[2015,10,14]],"date-time":"2015-10-14T00:00:00Z","timestamp":1444780800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0140574","type":"journal-article","created":{"date-parts":[[2015,10,14]],"date-time":"2015-10-14T18:24:54Z","timestamp":1444847094000},"page":"e0140574","update-policy":"http:\/\/dx.doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":2,"title":["Presence of Tablet Remnants of Nevirapine Extended-Release in Stools and Its Impact on Virological Outcome in HIV-1-Infected Patients: A Prospective Cohort Study"],"prefix":"10.1371","volume":"10","author":[{"given":"Yi-Chieh","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shu-Wen","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mao-Yuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sui-Yuan","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ching-Hua","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wang-Huei","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Szu-Min","family":"Hsieh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hsin-Yun","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hsi-Yen","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mon-Ro","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen-Chun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pei-Ying","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shang-Ping","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun-Yu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-Ching","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-Zhen","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chien-Ching","family":"Hung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shan-Chwen","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2015,10,14]]},"reference":[{"key":"ref1","article-title":"Guideline for the Use of Antiretroviral Agents in HIV-1-infected Adults and Aldolescents"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/S0140-6736(04)15997-7","article-title":"Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study","volume":"363","author":"F van Leth","year":"2004","journal-title":"Lancet"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ijid.2014.08.012","article-title":"Incidence and risk factors of skin rashes and hepatotoxicity in HIV-infected patients receiving nevirapine-containing combination antiretroviral therapy in Taiwan","volume":"29","author":"YT Tseng","year":"2014","journal-title":"Int J Infect Dis"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1310\/B5VU-FU5F-QNWC-UDCK","article-title":"Pharmacokinetics of nevirapine: once daily versus twice daily dosing in the 2NN study","volume":"6","author":"BS Kappelhoff","year":"2005","journal-title":"HIV Clin Trials"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1016\/j.clinthera.2011.08.003","article-title":"Bioavailability of extended-release nevirapine 400 and 300 mg in HIV-1: a multicenter, open-label study","volume":"33","author":"M Battegay","year":"2011","journal-title":"Clin Ther"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"759","DOI":"10.3851\/IMP1803","article-title":"Efficacy and safety of nevirapine extended-release once daily versus nevirapine immediate-release twice-daily in treatment-naive HIV-1-infected patients","volume":"16","author":"J Gathe","year":"2011","journal-title":"Antivir Ther"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/j.1468-1293.2011.00969.x","article-title":"Twenty-four-week efficacy and safety of switching virologically suppressed HIV-1-infected patients from nevirapine immediate release 200 mg twice daily to nevirapine extended release 400 mg once daily (TRANxITION)","volume":"13","author":"K Arasteh","year":"2012","journal-title":"HIV Med"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1111\/hiv.12090","article-title":"Finding of nevirapine extended release tablet remnants in stools does not threaten the success of combination antiretroviral therapy","volume":"15","author":"C Stephan","year":"2014","journal-title":"HIV Med"},{"key":"ref9","article-title":"Post-marketing experience with nevirapine extended release (XR) tablets: effectiveness and tolerability in a population-based cohort in British Columbia, Canada","author":"KL Lepik","year":"2014","journal-title":"Antivir Ther"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"e88497","DOI":"10.1371\/journal.pone.0088497","article-title":"Therapeutic drug monitoring and pharmacogenetic study of HIV-infected ethnic Chinese receiving efavirenz-containing antiretroviral therapy with or without rifampicin-based anti-tuberculous therapy","volume":"9","author":"KY Lee","year":"2014","journal-title":"PLoS One"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S0378-4347(98)00217-5","article-title":"Rapid determination of nevirapine in human plasma by ion-pair reversed-phase high-performance liquid chromatography with ultraviolet detection","volume":"713","author":"RP van Heeswijk","year":"1998","journal-title":"J. Chromatogr. B Biomed Sci Appl"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2165\/00003088-200746020-00002","article-title":"Efavirenz and nevirapine in HIV-1 infection\u2014is there a role for clinical pharmacokinetic monitoring?","volume":"46","author":"K Dahri","year":"2007","journal-title":"Clin Pharmacokinet"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1097\/00002030-200106150-00003","article-title":"High exposure to nevirapine in plasma is associated with an improved virological response in HIV-1-infected individuals","volume":"15","author":"AI Veldkamp","year":"2001","journal-title":"AIDS"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"599","DOI":"10.2165\/00003088-200342060-00009","article-title":"Low nevirapine plasma concentration predict virological failure in an unselected HIV-1-infected population","volume":"42","author":"TE de Vries-Sluijs","year":"2003","journal-title":"Clin Pharmacokinet"},{"key":"ref15","first-page":"670","article-title":"Tablets in stool? A common problem!","volume":"129","author":"LV Schuerch","year":"1999","journal-title":"Schweiz Med Wochenschr"},{"key":"ref16","unstructured":"Viramune XR, medication guide, U.S. Drug and Food Administration. Available at <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.fda.gov\/downloads\/drugs\/drugsafety\/ucm089818.pdf\" xlink:type=\"simple\">http:\/\/www.fda.gov\/downloads\/drugs\/drugsafety\/ucm089818.pdf<\/ext-link> Accessed: Febuary 6, 2015"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1097\/FPC.0b013e32836533a5","article-title":"Measuring the overall genetic component of nevirapine pharmacokinetics and the role of selected polymorphisms: towards addressing the missing heritability in pharmacogenetic phenotypes?","volume":"23","author":"JE Micheli","year":"2013","journal-title":"Pharmacogenet Genomics"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1128\/AAC.02294-12","article-title":"Pharmacokinetics of phase I nevirapine metabolites following a single dose and at steady state","volume":"57","author":"P Fan-Harvard","year":"2013","journal-title":"Antimicrob Agents Chemother"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0140574","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,11]],"date-time":"2024-06-11T20:19:46Z","timestamp":1718137186000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0140574"}},"subtitle":[],"editor":[{"given":"Paul Richard","family":"Harrigan","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2015,10,14]]},"references-count":18,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2015,10,14]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0140574","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,10,14]]}}}